Publications by authors named "Ronald Pruitt"

Claim this Profile
A
A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy.
Douglas K Rex, Raj Bhandari, Taddese Desta, Michael P DeMicco, Cynthia Schaeffer, Ronald Pruitt

Gastrointest Endosc· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.
Salam F Zakko, Glenn L Gordon, Uma Murthy, Shahriar Sedghi, Ronald Pruitt

Postgrad Med· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial.
M Scott Harris, Deborah Hartman, Brenda R Lemos, Emma C Erlich, Sharon Spence, Ronald Pruitt

J Crohns Colitis· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.
Glenn L Gordon, Salam Zakko, Uma Murthy, Shahriar Sedghi, Ronald Pruitt

J Clin Gastroenterol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
Stefan Zeuzem, Christophe Hézode, Jean-Pierre Bronowicki, Veronique Loustaud-Ratti, Francisco Gea, Ronald Pruitt

J Hepatol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computer-assisted personalized sedation for upper endoscopy and colonoscopy: a comparative, multicenter randomized study.
Daniel J Pambianco, John J Vargo, Ronald E Pruitt, Robert Hardi, James F Martin

Gastrointest Endosc· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Ellen J Scherl, Ronald Pruitt, Glenn L Gordon, Mark Lamet, Audrey Shaw

Am J Gastroenterol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
Monica M Bertagnolli, Craig J Eagle, Ann G Zauber, Mark Redston, Aurora Breazna, Ronald E Pruitt

Cancer Prev Res (Phila)· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Plicator procedure for the treatment of gastroesophageal reflux disease: a registry study.
John Birk, Ronald Pruitt, Gregory Haber, Isaac Raijman, Arthur Baluyut

Surg Endosc· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry.
Robert A Ganz, Bergein F Overholt, Virender K Sharma, David E Fleischer, Nicholas J Shaheen, Ronald E Pruitt

Gastrointest Endosc· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: A randomized, sham-controlled trial.
Richard Rothstein, Charles Filipi, Karel Caca, Ronald Pruitt, Klaus Mergener

Gastroenterology· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Celecoxib for the prevention of sporadic colorectal adenomas.
Monica M Bertagnolli, Craig J Eagle, Ann G Zauber, Mark Redston, Scott D Solomon, Ronald E Pruitt

N Engl J Med· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.
Robert Burakoff, Charles F Barish, Dennis Riff, Ronald Pruitt, William Y Chey

Inflamm Bowel Dis· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label, dose-ranging pilot study of 4 weeks of low-dose therapy with sodium phosphate tablets in chronically constipated adults.
Jeffrey Medoff, Seymour Katz, Pramod Malik, Daniel Pambianco, Ronald Pruitt

Clin Ther· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. Hanauer.
Lorin K Johnson, Ronald E Pruitt, Johnathan R B Green

Am J Gastroenterol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Ronald Pruitt, John Hanson, Michael Safdi, Lawrence Wruble, Robert Hardi

Am J Gastroenterol· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Douglas S Levine, Dennis S Riff, Ronald Pruitt, Lawrence Wruble, George Koval

Am J Gastroenterol· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis